Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2026-11-16
DOI
https://doi.org/10.1056/nejmoa2604058
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

Ania M. Jastreboff, Tina Buch, Nina Majlund Harder-Lauridsen, Antje Körner et al.
2 links
New England Journal of Medicine
Pharmacology and Obesity Treatment
article

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

Ania M. Jastreboff, Tina Buch, Nina Majlund Harder-Lauridsen, Antje Körner, Christine Frithioff‐Bøjsøe, Martin Wabitsch, Jens-Christian Holm, Shilpa Middolu, Michelle Van Name, Daniel Weghuber, Aaron S. Kelly
article en

Abstract

BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).

New England Journal of Medicine
University of Copenhagen (DK), University of Minnesota (US), Novo Nordisk (Denmark) (DK), Universität Ulm (DE), Paracelsus Medical University (AT), Yale Cancer Center (US), Helmholtz Zentrum München (DE), Yale University (US), University Hospital Leipzig (DE), Holbæk Sygehus (DK), University Hospital Ulm (DE), Novo Nordisk (India) (IN), Novo Nordisk Foundation Center for Basic Metabolic Research (DK), Leipzig University (DE)
Novo Nordisk
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon